Další formáty:
BibTeX
LaTeX
RIS
@article{819253, author = {Dvořáková, Dana and Lengerová, Martina and Pospíšilová, Jana and Palásek, Ivo and Mayer, Jiří}, article_number = {23}, keywords = {acute myeloid leukemia;nucleophosmin;minimal residual disease}, language = {eng}, issn = {0887-6924}, journal = {Leukemia}, title = {A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations}, volume = {4}, year = {2009} }
TY - JOUR ID - 819253 AU - Dvořáková, Dana - Lengerová, Martina - Pospíšilová, Jana - Palásek, Ivo - Mayer, Jiří PY - 2009 TI - A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations JF - Leukemia VL - 4 IS - 23 SP - 793-796 EP - 793-796 SN - 08876924 KW - acute myeloid leukemia;nucleophosmin;minimal residual disease N2 - Acute myeloid leukemia (AML) is a heterogeneous group of diseases affecting hematopoietic stem cells. In recent years, several novel molecular abnormalities have been identified in patients with AML, particularly in cases with normal karyotype. Among these, mutations of the nucleophosmin gene (NPM1) have been established as currently the most common abnormality in AML, found about half of all AML patients with normal karyotype. For the detection of NPM1 mutations on the molecular level, several different assays have been described, including direct sequencing, fragment analysis or high resolution melt analysis or high-performance liquid chromatography. NPM1 mutations might be also suitable as target structure for minimal residual disease monitoring. Here, we describe a novel quantitative assessment based on allelic discrimination assays and real-time PCR with mutation-specific minor groove binding (MGB) probes. This method offers an alternative to the standard routine laboratory evaluation and representing an efficient approach to the specific detection of NPM1 mutations without any false positivities caused by amplification on the wild-type alleles. ER -
DVOŘÁKOVÁ, Dana, Martina LENGEROVÁ, Jana POSPÍŠILOVÁ, Ivo PALÁSEK a Jiří MAYER. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations. \textit{Leukemia}. 2009, roč.~4, č.~23, s.~793-796. ISSN~0887-6924.
|